share_log

Morgan Stanley Initiates Coverage On Contineum Therapeutics With Overweight Rating, Announces Price Target of $25

Benzinga ·  Apr 30 05:15

Morgan Stanley analyst Jeffrey Hung initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and announces Price Target of $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment